Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma

• Status: Completed
• Trial end date: 2007-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this trial is to determine the appropriate dose of pixantrone to be used in this combination and obtain data on the combination's safety and activity profile.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: CTI BioPharma
• Treatments: Antibodies; BB 1101; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Fludarabine; Fludarabine phosphate; Pixantrone; Rituximab; Vidarabine

Criteria

Inclusion criteria

• Patients with relapsed or refractory indolent (low-grade) NHL

• Who have received 1-3 prior treatments with chemotherapy

Exclusion criteria

• Patients previously treated with fludarabine

• Prior treatment with rituximab (Rituxan), unless there was a complete response (CR) or partial response (PR) to that treatment

• Patients known to have an allergic reaction to rituximab, or to murine proteins.